The purpose of this study is to find out whether treatment with metronomic capecitabine will improve the survival of gastric cancer patients with stage III who had received standard treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
722
500 mg/m2 body surface area twice daily for 1 year; metronomic capecitabine group
observation
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
RECRUITINGDisease-free survival
DFS
Time frame: 3-year
Overall survival
OS
Time frame: 3-year
Side effects
Complications such as Nausea, vomiting, myelosuppression and Liver or kidney function disorder
Time frame: 1-year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.